lifestyle.ebusinessplanet.com

Author: BridgeBio Pharma, Inc.

BridgeBio to Present Additional Data from the Phase 3 FORTIFY Trial at the 2026 MDA Clinical & Scientific Conference

March 11, 2026
BridgeBio Reports Fourth Quarter and Full Year 2025 Financial Results and Commercial Updates

March 10, 2026
BridgeBio to Participate in March Investor Conferences

March 10, 2026
BridgeBio Pharma Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

March 9, 2026
BridgeBio to Report Fourth Quarter and Full Year 2025 Financial Results and Business Update on February 24, 2026 at 4:30 pm ET

March 9, 2026
BridgeBio Reports Positive Phase 3 Topline Results for Oral Infigratinib with the First Statistically Significant Improvements in Body Proportionality in Achondroplasia

March 8, 2026
CORRECTING and REPLACING — BridgeBio Pharma Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

January 27, 2026
BridgeBio Pharma Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

January 27, 2026